Clinical Trial

Changes in Salivary Asprosin, IL-39, IL-40 and IL-1β Levels in Diabetic Patients with Periodontitis

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2024 (before its estimated February 10, 2025 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to determine the relationships between asprosin, IL-39, IL-40 and IL-1β in saliva between individuals with and without diabetes and between individuals with periodontitis and healthy individuals and to determine the potential roles of these biomarkers that are multiplied in periodontal disease. The study aims to evaluate whether these biomarkers can be used for periodontal diagnosis or prognosis. The questions answered by the study are as follows: Do asprosin, IL-39, IL-40 and IL-1β biomarker levels differ between individuals with and without diabetes? Do these biomarker levels differ significantly between individuals with periodontitis and individuals who are healthy? Can these biomarkers be used in the early diagnosis or recording the progression of periodontal diseases?
Trial Details
NCT Number NCT06735313
Lead Sponsor Necmettin Erbakan University
Conditions Diabetes Mellitus, Periodontal Disease, Asprosin, Interleukin 1-beta
Enrollment 176 participants
Start Date 2025-01-10
Primary Completion 2025-02-10 (estimated)
Study Completion 2025-02-20 (estimated)
Updated on ClinicalTrials.gov 2024-12-16